Centessa Pharmaceuticals plc (NASDAQ:CNTA) Given Consensus Rating of “Moderate Buy” by Analysts

Centessa Pharmaceuticals plc (NASDAQ:CNTA) has earned a consensus rating of “Moderate Buy” from the five ratings firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $20.60.

Several research analysts recently commented on the stock. Oppenheimer reaffirmed an “outperform” rating and issued a $14.00 price target on shares of Centessa Pharmaceuticals in a research note on Wednesday, August 14th. Morgan Stanley raised their price target on shares of Centessa Pharmaceuticals from $8.00 to $11.00 and gave the stock an “equal weight” rating in a research note on Friday, June 21st. Jefferies Financial Group raised their price target on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. BMO Capital Markets increased their target price on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a report on Monday. Finally, Guggenheim increased their target price on shares of Centessa Pharmaceuticals from $20.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th.

Insider Activity

In other news, CEO Saurabh Saha sold 4,169 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $12.32, for a total value of $51,362.08. Following the sale, the chief executive officer now directly owns 827,755 shares in the company, valued at approximately $10,197,941.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Saurabh Saha sold 4,169 shares of the stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $12.32, for a total value of $51,362.08. Following the completion of the transaction, the chief executive officer now directly owns 827,755 shares of the company’s stock, valued at approximately $10,197,941.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Gregory M. Weinhoff sold 25,000 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $15.00, for a total transaction of $375,000.00. Following the completion of the transaction, the insider now directly owns 223,369 shares of the company’s stock, valued at $3,350,535. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 216,873 shares of company stock worth $3,472,000. Corporate insiders own 11.59% of the company’s stock.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Quarry LP purchased a new position in shares of Centessa Pharmaceuticals in the 4th quarter valued at approximately $48,000. Sandia Investment Management LP acquired a new stake in Centessa Pharmaceuticals during the 2nd quarter valued at approximately $90,000. Fred Alger Management LLC acquired a new stake in Centessa Pharmaceuticals during the 2nd quarter valued at approximately $99,000. EntryPoint Capital LLC acquired a new stake in Centessa Pharmaceuticals during the 1st quarter valued at approximately $109,000. Finally, Trexquant Investment LP acquired a new stake in Centessa Pharmaceuticals during the 4th quarter valued at approximately $114,000. 82.01% of the stock is owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals Trading Down 3.5 %

Shares of CNTA opened at $15.71 on Thursday. Centessa Pharmaceuticals has a twelve month low of $5.15 and a twelve month high of $17.59. The company has a market cap of $1.58 billion, a P/E ratio of -11.06 and a beta of 1.44. The company has a current ratio of 13.29, a quick ratio of 13.29 and a debt-to-equity ratio of 0.27. The company’s fifty day simple moving average is $12.15 and its 200-day simple moving average is $10.60.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its earnings results on Tuesday, August 13th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02). As a group, analysts expect that Centessa Pharmaceuticals will post -1.61 EPS for the current year.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.